Brussels, 5 June 2025

Following the adoption of the Council position on the pharmaceutical legislation, EuropaBio regrets the missed opportunity to fully leverage Europe’s potential for biotech and life sciences innovation.

Despite some improvements, there is a risk to halt attractiveness and competitiveness of the EU ecosystem. Simpler and predictable regulations are essential to improve the European biotech ecosystem and support long-term investments for innovators.

EuropaBio calls for a more ambitious pharmaceutical legislation that addresses the competitive challenges currently faced by Europe. A supportive GPL will help building a strong EU Biotech Act, enabling the EU to position as a leading hub for biotechnology and innovation. 

Dr Claire Skentelbery, Director General of EuropaBio, commented, “The General Pharmaceutical Legislation must reflect the full potential of Europe’s biotech and life sciences sectors. Without it, we risk undermining innovation efforts that can drive resilience, competitiveness, and better health outcomes for citizens.”

EuropaBio remains committed to constructive engagements during trilogues but calls on policymakers to use the EU pharmaceutical legislation to kickstart EU path to prosperity, resilience, and leadership through biotechnology.